 |
|
|
| |
CHARACTERIZATION OF HEAVILY TREATMENT-EXPERIENCED HIV-1-INFECTED CLINICAL TRIAL
PARTICIPANTS INFECTED WITH SARS-COV-2 COVID-19:
FOSTEMSAVIR BRIGHTE PHASE 3 CLINICAL TRIAL
|
| |
| |
poster pdf attached
ID Week 2021 Sept 29-Oct 3
Download the PDF here
Shiven Chabria,1 Stéphane De Wit,2 Amy Pierce,3 Bronagh Shepherd,4 Mike Warwick-Sanders,4 Fangfang Du,5 Marcia Wang,5 Andrew Clark,6 Peter Ackerman1
1ViiV Healthcare, Branford, CT, USA; 2CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium; 3ViiV Healthcare, Research Triangle Park, NC, USA; 4GlaxoSmithKline, Brentford, UK; 5GlaxoSmithKline, Collegeville, PA, USA; 6ViiV Healthcare, Brentford, UK
|
| |
|
|
|
|
|
